Yahoo Finance9h
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study
Competition has increased for some of Jakafi’s approved indications. The FDA’s approval of GSK plc’s GSK Ojjaara for the treatment of intermediate or high-risk MF, including primary MF or secondary MF ...
Medindia4d
AZURITY PHARMACEUTICALS, INC ANNOUNCES FDA APPROVAL OF DANZITEN™ (nilotinib) tablets, THE FIRST AND ONLY NILOTINIB WITH NO MEALTIME RESTRICTIONS
Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten™, the first and only nilotinib with no mealtime restrictions indicated for adult patients ...
Daily5d
GSK Ojjaara approved in Canada for treatment of myelofibrosis in adults who have moderate to severe anemia
Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Pharmabiz5d
Health Canada approves GSK’s Ojjaara for the treatment of myelofibrosis in adults who have moderate to severe anaemia
Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...
Pharmaceutical Technology6d
Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients
GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...